AD is an extremely complex, polygenic and multifactorial disease that incorporates several biochemical proteins such as Tau, APP, Aβ, etc. Since AD is so complex, the development of new pharmaceuticals is necessary to combat such a detrimental disease. This evidence concerns the gene MAPT and Alzheimer disease.